L3VLUP
ProSign in

BCRX in the 13F filings

Biocryst Pharmaceuticals Inc · CUSIP 09058V103

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Mar 2024
the date the book describes
Filed
15 May 2024
latest of these filings; the earliest 15 May 2024
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q4 2023 and Q1 2024; 2 listed it in both
Shares listed
3,153,935
combined, among listed positions
Reported value
$16m
combined, at the quarter end

Among the 93 comparable managers: 3 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing BCRX in Q1 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q4 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Two Sigma Advisers LP2,473,412$13munder 0.1%Added+205,40015 May 2024 (the filing on sec.gov)
PDT Partners LLC380,523$1.9m0.18%Added+69,32515 May 2024 (the filing on sec.gov)
Hudson Bay Capital Management LP300,000$1.5munder 0.1%Addedn.a.15 May 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q4 2023 to Q1 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
3 in Q3 2024 to 7 in Q2 2026

Tracked managers listing it, at least.

0246820142017201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
BCRX by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20131$692kn.a.n.a.
Q1 20141$632kn.a.n.a.
Q2 20142$34mn.a.n.a.
Q2 20153$165mn.a.n.a.
Q3 20152$114mn.a.n.a.
Q3 20161$714kn.a.n.a.
Q4 20161$828kn.a.n.a.
Q1 20173$28mn.a.n.a.
Q2 20171$718kn.a.n.a.
Q1 20181$2.7mn.a.n.a.
Q2 20181$64mn.a.n.a.
Q3 20182$95mn.a.n.a.
Q4 20181$99mn.a.n.a.
Q1 20191$100mn.a.n.a.
Q2 20191$8.5mn.a.n.a.
Q3 20193$20mn.a.n.a.
Q4 20193$39mn.a.n.a.
Q1 20204$15mn.a.n.a.
Q2 20204$53mn.a.n.a.
Q3 20202$4.8mn.a.n.a.
Q4 20203$33mn.a.n.a.
Q1 20211$31mn.a.n.a.
Q2 20213$88mn.a.n.a.
Q3 20216$119mn.a.n.a.
Q4 20214$79mn.a.n.a.
Q1 20225$83mn.a.n.a.
Q2 20224$60mn.a.n.a.
Q3 20227$85mn.a.n.a.
Q4 20228$111mn.a.n.a.
Q1 20236$59mn.a.n.a.
Q2 20234$53mn.a.n.a.
Q3 20234$44mn.a.n.a.
Q4 20232$15m11
Q1 20243$16m30
Q2 20243$30m12
Q3 20243$34m21
Q4 20242$23m20
Q1 20254$50m40
Q2 20257$170m61
Q3 20255$74m40
Q4 20256$138m1322
Q1 20266$170m1716
Q2 20267$187m2212

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

BCRX and GILD →BCRX and AMGN →BCRX and ARGX →Choose a stock to compare with BCRX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own BCRX, latest filings →Back to the 13F Explorer →